As per American Optometric Association, “Presbyopia is expected to impact approximately 123 million US residents by 2020. As the geriatric population is projected to grow in the United States, this disease will become more common with age; hence, DelveInsight’s analysts estimate that the prevalence rate will rise as well.”
Current clinical management in the Presbyopia treatment market includes usage of the off-label treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. As per the DelveInsight, “a majority (3/4th cases) of the Presbyopia patients use eyeglasses to correct close-up vision problems. In terms of revenue, eyeglasses consist of nearly half of the US Presbyopia treatment market in 2018”.
However, some of the key companies in the Presbyopes treatment market such as Eyenovia, Orasis Pharmaceuticals, Allergan, Novartis, Ocuphire Pharma, Visus Therapeutics, are striving to change the picture through their novel pharmacotherapies.
For more detailed information, visit: Presbyopia Pharmacological Treatment